TIMP1 and adenocarcinoma: Despite their simplicity (with the exception of TIMP-1 in PROMISE which is not routinely measured in clinical practice) and external validation, there has been suggestion that alternative scoring systems are necessary to correct for regional demographics variation, for example in areas with high rates of EGFR adenocarcinoma mutations (49) and target specific tumour types.